| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-08-10 |
| タイトル |
|
|
タイトル |
Loco-regional therapy for isolated locoregional lymph node recurrence of breast cancer: Focusing on surgical treatment with combined therapy |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Breast cancer |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
locoregional lymph node metastases |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
axillary recurrence |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
supraclavicular recurrence |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Terata, Kaori
Yamaguchi, Ayuko
Ibonai, Ayano
Imai, Kazuhiro
Wakita, Akiyuki
Sato, Yusuke
Motoyama, Satoru
Minamiya, Yoshihiro
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Advances have been made in systemic as well as locoregional treatment of primary breast cancer. Evidence, based established therapeutic strategies, for isolated locoregional lymph node recurrence is not yet sufficient. In this series, we focused especially on isolated axillary lymph node recurrence (AR) and supraclavicular lymph node recurrence (SR) in patients receiving systemic and/or radiation therapy combined with surgery. Disease free survival (DFS) in patients with AR ranged from 20 to 36 months. From 69% to 77% of all patients underwent surgical excision. The 5-year overall survival (OS) ranged from 39% to 46%. Positive lymph node metastases of primary cancer, size of the primary tumor, and R0 resection were associated with good outcomes. Longer DFS is associated with good outcomes. Limited SR data showed DFS to range from 25–27%. Median progression free survival (PFS) was 18 months, 5-year OS rates were 24–42%, and 5-year OS were 29–34 months. Combination therapy was an independent factor associated with better PFS as compared to local therapy only. Salvage treatment and grade of the primary tumor significantly were associated with OS on multivariate analysis. Available data, retrospective and not randomized, showed therapy combining systemic treatments and/or radiotherapy with surgery might contribute to good local control, better PFS, and longer OS. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
en : Translational Cancer Research
巻 9,
号 8,
p. 5038-5043,
発行日 2020
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
2218-676X |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2219-6803 |
| 出版者 |
|
|
出版者 |
Translational Cancer Research |
|
言語 |
en |
| 関連情報 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.21037/tcr-20-1690a |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
© Translational Cancer Research. All rights reserved. |
iA_2021_23 (192.4 kB)
